EcoDrugPlus

Atpase, Na+/k+ Transporting, Alpha 3 Polypeptide

Ensembl ID : ENSMSIG00000010376
Gene Symbol: ATP1A3
1 Cross references
149 Possible Orthologues:

Atpase, Na+/k+ Transporting, Alpha 4 Polypeptide

Ensembl ID : ENSMSIG00000007957
Gene Symbol: ATP1A4
1 Cross references
579 Possible Orthologues:

Atpase, Na+/k+ Transporting, Beta 2 Polypeptide

Ensembl ID : ENSMSIG00000025884
Gene Symbol: ATP1B2
1 Cross references
289 Possible Orthologues:

Atpase, Na+/k+ Transporting, Beta 3 Polypeptide

Ensembl ID : ENSMSIG00000015722
Gene Symbol: ATP1B3
1 Cross references
314 Possible Orthologues:

Axl Receptor Tyrosine Kinase

Ensembl ID : ENSMSIG00000025298
Gene Symbol: AXL
1 Cross references
212 Possible Orthologues:

Araf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSMSIG00000016384
Gene Symbol: ARAF
1 Cross references
206 Possible Orthologues:

B Cell Leukemia/lymphoma 2

Ensembl ID : ENSMSIG00000014587
Gene Symbol: BCL2
1 Cross references
242 Possible Orthologues:

Bcl2-Like 1

Ensembl ID : ENSMSIG00000001188
Gene Symbol: BCL2L1
1 Cross references
302 Possible Orthologues:

Bcl2-Like 2

Ensembl ID : ENSMSIG00000017004
Gene Symbol: BCL2L2
1 Cross references
79 Possible Orthologues:

Braf Transforming Gene

Ensembl ID : ENSMSIG00000003138
Gene Symbol: BRAF
1 Cross references
235 Possible Orthologues:

Bruton Agammaglobulinemia Tyrosine Kinase

Ensembl ID : ENSMSIG00000016186
Gene Symbol: BTK
1 Cross references
221 Possible Orthologues:

C-Type Lectin Domain Family 4, Member A2

Ensembl ID : ENSMSIG00000015992
Gene Symbol: CLEC4A2
1 Cross references
721 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).